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Experimental and human studies indicate that macrophages play a key role 
within the diseased kidney and represent a target for novel therapies. This 
brief review outlines the involvement and nature of macrophages in renal 
disease and highlights the phenotypic plasticity of these cells and their 
responsiveness to the renal microenvironment.  
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Monocytes and macrophages are key components of the mononuclear 
phagocyte system (1). Whilst dendritic cells are specialised for immune 
surveillance and the activation of the adaptive immune system, macrophages 
are highly phagocytic cells that are involved in tissue development and 
homeostasis, inflammation, fibrosis as well as tissue repair (2, 3). Difficulties 
can arise, however, as there is significant overlap between the cell surface 
markers of macrophages and dendritic cells (e.g. F4/80, CD11b and CD11c) 
such that the nomenclature can be confusing and experimental data open to 
more than one interpretation (1, 2, 4). For example, the majority of resident 
renal mononuclear phagocytes express CD11c that has often been used as a 
marker of dendritic cells. However, analysis of renal F4/80+CD11c+ cells for 
cell surface markers and function indicate that they express scavenger 
receptors (CD206 and CD204) and are very phagocytic cells with limited 
capacity to present antigen – typical features of macrophages (5). Additional 
studies highlight the fact that the kidney contains multiple sub-populations of 
cells with features of dendritic cells or macrophages (6). 
 
During disease the resident macrophage population is increased by the 
recruitment of monocyte from the circulation driven by chemokines such as 














expression of the monocyte/macrophage growth factor colony stimulating 
factor-1 (CSF-1) is increased in the inflamed kidney (7, 8). CSF-1 is an 
important and mediates the survival, proliferation and differentiation of 
monocytes and macrophages such that increased CSF-1 expression leads to 
significant macrophage proliferation that expands renal macrophage number 
(9-12). 
 
Macrophages encounter myriad stimuli within normal, injured, healing and 
fibrotic tissues such as hypoxia, cytokines, chemokines, reactive oxygen 
species, apoptotic cells and debris. Macrophages need to integrate these 
potentially competing signals in order to adopt a phenotype deemed 
appropriate to the situation. Experimental in vitro and in vivo studies have 
shown that macrophages may adopt a range of diverse phenotypes broadly 
categorised as the pro-inflammatory M1 phenotype or wound healing M2 
phenotype (13).  
 
Exposure to Toll-like receptor (TLR) ligands such as pathogen-derived 
endotoxin or damage-associated molecular patterns (DAMPs) released during 
sterile tissue injury (14) and cytokines such as interferon-γ (IFNγ) induce M1 
macrophage polarisation. M1 macrophages upregulate cytotoxic and 
microbicidal mediators such as tumour necrosis factor-α (TNF-α) and 
inducible nitric oxide synthase (iNOS) and may exhibit increased expression 
of Ly6C and HLA-DR. Although the M1 phenotype is appropriate for dealing 
with infective pathogens it is associated with tissue injury in sterile 
inflammation.  
 
Transcription factors are involved in regulating the genes involved in 
macrophage programming. For example, the transcription factor interferon 
regulatory factor 5 (IRF5) plays a key role in the induction of the pro-
inflammatory M1 phenotype such that siRNA mediated silencing of IRF5 can 
limit M1 macrophage activation and promote M2 macrophage activation in 
vivo with resultant amelioration of tissue injury in models of cardiac and spinal 















Exposure to cytokines such as IL-10 and IL-4, immune complexes as well as 
the ingestion of apoptotic cells induces M2 macrophage polarisation. M2 
macrophages upregulate arginase activity and typically express increased 
levels of scavenger receptors such as CD206, CD204 and CD163. Although 
M2 macrophages are anti-inflammatory and termed wound healing they are 
often associated with maladaptive renal fibrosis.  
 
Macrophages may exert immunoregulatory functions and cells termed 
regulatory macrophages (Mregs) have been implicated in the development of 
tolerance to allografts (17). Mregs express few M1 or M2 markers with 
production of IL-10 being key for their immunosuppressive actions that include 
the inhibition of CD8+ T cell responses and induction of regulatory T cells. 
Recent work, albeit using a murine vascularised cardiac transplant model, 
suggests that Mreg generation requires the actions of CSF-1 and TLR-4 
engagement (18). Mregs expressed the cell surface marker DC-SIGN and 
were key to the induction of tolerance by costimulatory blockade as inhibition 
of these cells abrogated tolerance (18).  
 
Despite the utility of the M1/M2 paradigm it should be appreciated that the 
biological reality is much more complex with subtle but important differences 
between different activation stimuli (19-21). As a result, many additional 
phenotypes will undoubtedly exist including mixed macrophage phenotypes 
where M1 and M2 markers may co-exist occur (22, 23). 
 
Insights from experimental models of renal disease and 
macrophage depletion studies 
 
In an attempt to mimic human disease, investigators have developed multiple 
experimental models of renal injury in rodents that can be employed in mice 
deficient in chemokines (CCL2) or chemokine receptors (CCR2 and CX3CR1) 
involved in monocyte/macrophage recruitment. This strategy has 














experimental models including nephrotoxic nephritis (24), diabetic 
nephropathy (25) and renal ischaemia-reperfusion injury (IRI) (26).  
 
Liposomal clodronate is cytotoxic following uptake by cells and has been a 
useful tool to deplete monocytes/macrophages in various organs as it targets 
the phagocytic macrophage. Studies have shown renal protection following 
clodronate-mediated macrophage depletion in multiple models of kidney injury 
or disease including cystic renal disease (27-31). The development of 
transgenic mice in which the expression of the human or simian diphtheria 
toxin receptor (DTR) is under the control of the CD11b promoter has allowed 
the relative selective depletion of CD11b+ monocytes and macrophages by 
the administration of diphtheria toxin (DT) to mice (32). This system has 
demonstrated reduced injury or fibrosis following monocyte/macrophage 
depletion in models of fibrosis (33), nephrotoxic nephritis (34) and murine 
transplantation (35). Interestingly, no protection was evident in murine renal 
IRI (36) though the addition of clodronate to DT conferred protection (37).  
 
It is important to bear in mind that macrophage are not always injurious or 
pro-fibrotic as the critical reparative role of the macrophage has been 
highlighted by studies of macrophage depletion using liposomal clodronate or 
CD11b/DTR mice in the reparative phase of the renal IRI model. This phase is 
characterised by the restoration of renal function and tubular repair and 
macrophage depletion is highly detrimental as it results in increased mortality, 
prolonged injury and failure of tubular repair (38-41). During renal repair, 
macrophages are an important source of mediators such as Wnt7b and IL-22 
that promote tubular epithelial proliferation (40, 42).  
 
Lastly, it should be noted that few studies have attempted to dissect the roles 
of resident macrophages versus infiltrating monocyte-derived macrophages to 
determine which macrophage population is key to injury and fibrosis as 
interventions to deplete macrophages typically exert effects upon both 
populations. In order to explore this question, Lin et al used bone marrow 
transplantation to generate chimeric CD11b/DTR mice such that the 














infiltrating monocyte-derived macrophages (43). These studies used the 
model of unilateral ureteric obstruction that exhibits marked interstitial fibrosis 
with a dramatic macrophage infiltrate. DT-induced depletion of DTR+ 
infiltrating monocyte-derived macrophages was markedly anti-fibrotic. In 
contrast, the targeted depletion of DTR+ resident macrophages did not affect 
fibrosis despite the fact that they constituted up to 40% of the total 
macrophage population.   
 
Although the majority of patients with significant renal disease are elderly, the 
vast majority experimental rodent studies are undertaken in young animals. It 
is pertinent that aged mice develop much worse acute kidney injury following 
renal IRI (44, 45) with the induction of the cytoprotective enzyme 
hemeoxygenase-1 (HO-1) being less robust compared to young mice. The 
administration of the potent HO-1 inducer heme arginate strongly protected 
aged mice from renal IRI with monocyte/macrophage HO-1 expression being 
critical. Other macrophage functions such as the phagocytosis of apoptotic 
cells have been noted to be abnormal in aging mice (46) with a defect in both 
resident and recruited macrophage phagocytosis evident. It is thus likely that 
the monocytes and macrophages of elderly patients may behave differently to 
younger individuals. 
 
Although the number and phenotype of endogenous macrophages may be 
the target of interventions, it is also of interest that the exogenous 
administration of anti-inflammatory or M2 macrophages can ameliorate both 
acute and chronic experimental disease (47-49). 
 
The Regulation of Macrophage Phenotype In Vivo  
 
It thus appears that macrophages may be cytotoxic (M1), reparative (M2) or 
pro-fibrotic (M2) within the kidney. An important question that has been 
addressed recently is whether these differing M1/M2 macrophage phenotypes 
are directly derived from either resident macrophages or recruited monocytes 














result of changes in the renal microenvironment. Lee et al performed elegant 
adoptive transfer experiments involving the administration of fluorescently 
labelled bone marrow-derived macrophages programmed in vitro to adopt a 
M1 phenotype to mice shortly after the induction of renal IRI (39). The labelled 
cells were retrieved at later time points and were found to have a M2 
phenotype as they exhibited downregulation of iNOS expression and 
upregulation of CD206 expression. This study indicated that macrophage 
phenotype is dynamic and can evolve during the injury and repair phase of 
renal injury (Figure 1).  
 
Further work has highlighted the importance of the renal expression of 
macrophage growth and differentiation factors by tubular epithelial cells in the 
beneficial reprogramming of pro-inflammatory M1 macrophages to reparative 
M2 macrophages with a role for both CSF-1 (also termed macrophage- colony 
stimulating factor, M-CSF) (50, 51) and granulocyte macrophage-colony 
stimulating factor (GM-CSF) (52). The effect of CSF-1 upon M1 macrophage 
reprogramming may be via the induction of microRNA-24 (53) though renal 
data is lacking at present.  
 
In the light of the beneficial role of CSF-1 in modulating the phenotype of 
macrophages, it is intriguing that strategies to inhibit the function of CSF-1 
using function blocking antibodies or drugs that target activation of the CSF-1 
receptor have been shown to be protective in a wide range of experimental 
models (54-58). These studies suggest that reducing macrophage 
proliferation and number is beneficial in situations where there are excessive 
numbers of macrophages driving injury or fibrosis. In contrast, the exogenous 
administration of CSF-1 following experimental murine IRI significantly 
improved renal repair suggesting that augmenting the population of 
macrophages involved in renal repair is highly beneficial (59).  
 
Recent work has suggested an important role for retinoic acid in modulating 
macrophage phenotype via the direct inhibition of M1 macrophages and the 
promotion of tubular cell induction of M2 macrophages indicating that there 















Macrophages – Key Players in Human Disease 
 
Macrophages are present in various human renal disease including various 
causes of chronic kidney disease including diabetes (61, 62), polycystic 
kidney disease, kidney allograft rejection (63), chronic allograft nephropathy 
(64, 65) and acute kidney injury (22, 65). Studies have demonstrated a strong 
association between the extent of macrophage infiltration and functional 
outcome (66). A recent study of paediatric kidney transplant recipients with 
chronic allograft nephropathy demonstrated CD163+ M2 macrophage in 
fibrotic areas of the kidney with CD163+ cell number correlating with 
interstitial fibrosis and renal function (64). Interestingly, urine CD163 levels 
also correlated with fibrosis suggesting the potential for using urine markers of 
macrophage phenotype as a biomarker of renal scarring. Similarly, in a study 
of 1-year renal transplant biopsies from adult transplant recipients the 
numbers of CD206+ macrophages correlated with both fibrosis and renal 
function at 3 years following transplantation (67). Additional recent work 
highlights the involvement of macrophages in lupus nephritis (68) with the 
number of interstitial CD68+ macrophages correlating with renal function and 
fibrosis. A minority of macrophages were iNOS+ M1 macrophages with the 
majority being positive for the M206 markers CD206 and CD163. The 
proportions of iNOS+, CD206 or CD163 varied between glomerular and 
interstitial compartments and between classes of lupus nephritis. The 
predominance of M2 macrophages over M1 macrophages may reflect 
patients undergoing a renal biopsy at a later stage of disease than is usual in 
experimental models of lupus nephritis as well as the potential effects of drug 
treatment such as steroids that can induce a M2 phenotype. 
 
Potential Therapeutic Approaches to Target Macropha ges 
In view of the complexity of macrophage phenotype and their involvement in 
multiple aspects of kidney disease (acute kidney injury, renal repair, 
glomerulonephritis, fibrosis etc) the timing of interventions directed to 














considered.  Some therapies currently in use will exert effects upon 
macrophages. For example, glucocorticoids increase the phagocytic 
capabilities of macrophages and induce an anti-inflammatory phenotype (69). 
Potential strategies to limit macrophage numbers include the inhibition of 
chemokines involved in the recruitment of monocytes to the kidney and there 
are clinical trials in progress that are targeting the CCL2/CCR2 axis in patients 
with renal disease such as diabetic nephropathy. There is also potential for 
the inhibition of growth factors such as CSF-1 in situations where macrophage 
are driving injury and/or fibrosis or the administration of exogenous CSF-1 to 
bolster a reparative macrophage population. Although macrophage cell 
therapy for inflammatory renal disease has not been undertaken thus far, the 
effect of administering donor-derived regulatory macrophages generated in 
vitro was examined in 2 patients undergoing live donor kidney transplantation 
(70). Graft function remained stable over 3 years with the patients being 
maintained on tacrolimus monotherapy. In addition, the peripheral blood gene 
signature of these patients was similar to that found in tolerant patients. The 
administration of Mregs is now being tested in the active ONE Study Mreg trial 





Macrophages are remarkably versatile cells and, although they may assist 
tissue remodelling, they are often associated with tissue injury and disease 
progression. A deeper understanding of the cellular and molecular 
mechanisms that mediate the diverse functions of macrophages in renal 
disease should allow the development of novel therapies that may have 



















Figure 1 - Macrophage phenotype within the diseased  kidney   
Renal injury and inflammation leads to the release of pro-inflammatory 
mediators including chemokines, cytokines and damage associated molecular 
patterns (DAMPs). These and other mediators result in the induction of a pro-
inflammatory cytotoxic M1 macrophage. Upregulated tubular expression of 
colony stimulating factor-1 (CSF-1) expression induces macrophage 
proliferation that may promote ongoing renal injury in the presence of 
persistent inflammation. During repair, various mediators including IL-10, 
apoptotic cells and the growth factors CSF-1 and granulocyte macrophage 
colony stimulating factor-1 (GM-CSF) promote the phenotypic switch to anti-
inflammatory wound healing M2 macrophages that may promote the 
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